|
1
|
Bailey P: Intracranial sarcomatous tumors
of leptomeingeal origin. Arch Surg. 18:1359–1402. 1929. View Article : Google Scholar
|
|
2
|
Siegal T and Bairey O: Primary CNS
lymphoma in the elderly: The challenge. Acta Haematol. 141:138–145.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mulazzani M, Huber M, Borchard S, Langer
S, Angele B, Schuh E, Meinl E, Dreyling M, Birnbaum T, Straube A,
et al: APRIL and BAFF: Novel biomarkers for central nervous system
lymphoma. J Hematol Oncol. 12:1022019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Braggio E, Van Wier S, Ojha J, McPhail E,
Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, et
al: Genome-wide analysis uncovers novel recurrent alterations in
primary central nervous system lymphomas. Clin Cancer Res.
21:3986–3994. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapuy B, Roemer MG, Stewart C, Tan Y, Abo
RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, et
al: Targetable genetic features of primary testicular and primary
central nervous system lymphomas. Blood. 27:869–881. 2016.
View Article : Google Scholar
|
|
6
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Villano JL, Koshy M, Shaikh H, Dolecek TA
and McCarthy BJ: Age, gender, and racial differences in incidence
and survival in primary CNS lymphoma. Br J Cancer. 105:1414–1418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Neill BP, Decker PA, Tieu C and Cerhan
JR: The changing incidence of primary central nervous system
lymphoma is driven primarily by the changing incidence in young and
middle-aged men and differs from time trends in systemic diffuse
large B-cell non-Hodgkin's lymphoma. Am J Hematol. 88:997–1000.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deangelis LM and Iwamoto FM: An update on
therapy of primary central nervous system lymphoma. Hematol Am Soc
Hematol Educ Program. 2006:311–316. 2006. View Article : Google Scholar
|
|
10
|
Omuro AM, Taillandier L, Chinot O, Carnin
C, Barrie M and Hoang-Xuan K: Temozolomide and methotrexate for
primary central nervous system lymphoma in the elderly. J Neuro
Oncol. 85:207–211. 2007. View Article : Google Scholar
|
|
11
|
Roth P and Hoang-Xuan K: Challenges in the
treatment of elderly patients with primary central nervous system
lymphoma. Curr Opin Neurol. 27:697–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grommes C and DeAngelis LM: Primary CNS
lymphoma. J Clin Oncol. 35:2410–2418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schabet M: Epidemiology of primary CNS
lymphoma. J Neurooncol. 43:199–201. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Enblad G, Martinsson G, Baecklund E,
Hesselager G, Sundström C, Amini RM and Hagberg H: Population-based
experience on primary central nervous system lymphoma 2000-2012:
The incidence is increasing. Acta Onco. 156:599–607. 2017.
View Article : Google Scholar
|
|
15
|
Reni M, Ferreri AJ, Guha-Thakurta N, Blay
JY, Dell'Oro S, Biron P and Hochberg FH: Clinical relevance of
consolidation radiotherapy and other main therapeutic issues in
primary central nervous system lymphomas treated with upfront
high-dose methotrexate. Int J Radiat Oncol Biol Phys. 51:419–425.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan SM, Hutnik CM, Heathcote JG, Orton RB
and Banerjee D: Iris lymphoma in a pediatric cardiac transplant
recipient: Clinicopathologic findings. Ophthalmology.
107:1479–1482. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matinella A, Lanzafame M, Bonometti MA,
Gajofatto A, Concia E, Vento S, Monaco S and Ferrari S:
Neurological complications of HIV infection in pre-HAART and HAART
era: A retrospective study. J Neurol. 262:1317–1327. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engels EA, Biggar RJ, Hall HI, Cross H,
Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS
and Goedert JJ: Cancer risk in people infected with human
immunodeficiency virus in the United States. Int J Cancer.
123:187–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shiels MS, Pfeiffer RM, Besson C, Clarke
CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G and Engels
EA: Trends in primary central nervous system lymphoma incidence and
survival in the U.S. Br J Haematol. 174:417–424. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bathla G and Hegde A: Lymphomatous
involvement of the central nervous system. Clin Radiol. 71:602–609.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morell AA, Shah AH, Cavallo C, Eichberg
DG, Sarkiss CA, Benveniste R, Ivan ME and Komotar RJ: Diagnosis of
primary central nervous system lymphoma: A systematic review of the
utility of CSF screening and the role of early brain biopsy.
Neurooncol Pract. 6:415–423. 2019.PubMed/NCBI
|
|
22
|
Miller B, Sirotkin I and Martinez C:
Review of radiologic considerations in an immunocompetent patient
with primary central nervous system lymphoma. Fed Pract. 36(Suppl
5): S51–S53. 2019.PubMed/NCBI
|
|
23
|
Lin X, Khan IRA, Seet YHC, Lee HY and Yu
WY: Atypical radiological findings of primary central nervous
system lymphoma. Neuroradiology. 62:669–676. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scott BJ, Douglas VC, Tihan T, Rubenstein
JL and Josephson SA: A systematic approach to the diagnosis of
suspected central nervous system lymphoma. JAMA Neurol. 70:311–319.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferreri AJM: Therapy of primary CNS
lymphoma: Role of intensity, radiation, and novel agents.
Hematology Am Soc Hematol Educ Program. 2017:565–577. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Malikova H, Burghardtova M, Koubska E,
Mandys V, Kozak T and Weichet J: Secondary central nervous system
lymphoma: Spectrum of morphological MRI appearances. Neuropsychiatr
Dis Treat. 14:733–740. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Green K and Hogg JP: Central Nervous
System Lymphoma. StatPearls. StatPearls Publishing; Treasure
Island, FL: 2020
|
|
28
|
Blay JY, Ongolo-Zogo P, Sebban C, Carrie
C, Thiesse P and Biron P: Primary cerebral lymphomas: Unsolved
issues regarding first-line treatment, follow-up, late neurological
toxicity and treatment of relapses. The FNCLCC. French Fédération
Nationale des Centres de Lutte contre le Cancer. Ann Oncol.
11(Suppl 1): S39–S44. 2000. View Article : Google Scholar
|
|
29
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identifified by
gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pasqualucci L and Dalla-Favera R: The
genetic landscape of diffuse large B-cell lymphoma. Semin Hematol.
52:67–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar
|
|
32
|
Hoang-Xuan K, Bessell E, Bromberg J,
Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C,
Abacioglu U, et al: Diagnosis and treatment of primary CNS lymphoma
in immunocompetent patients: Guidelines from the European
Association for Neuro-Oncology. Lancet Oncol. 16:e322–e332. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
von Baumgarten L, Illerhaus G, Korfel A,
Schlegel U, Deckert M and Dreyling M: The diagnosis and treatment
of primary CNS LYmphoma. Dtsch Arztebl Int. 115:419–426.
2018.PubMed/NCBI
|
|
34
|
Antinori A, De Rossi G, Ammassari A,
Cingolani A, Murri R, Di Giuda D, De Luca A, Pierconti F,
Tartaglione T, Scerrati M, et al: Value of combined approach with
thallium-201 single-photon emission computed tomography and
Epstein-Barr virus DNA polymerase chain reaction in CSF for the
diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol.
17:554–560. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sasagawa Y, Akai T, Tachibana O and Iizuka
H: Diagnostic value of interleukin-10 in cerebrospinal fluid for
diffuse large B-cell lymphoma of the central nervous system. J
Neurooncol. 121:177–183. 2015. View Article : Google Scholar
|
|
36
|
Song Y, Zhang W, Zhang L, Wu W, Zhang Y,
Han X, Yang C, Zhang L and Zhou D: Cerebrospinal fluid IL-10 and
IL-10/IL-6 as accurate diagnostic biomarkers for primary central
nervous system large B-cell lymphoma. Sci Rep. 6:386712016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rubenstein JL, Wong VS, Kadoch C, Gao HX,
Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, et
al: CXCL13 plus interleukin 10 is highly specific for the diagnosis
of CNS lymphoma. Blood. 121:4740–4748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Viaccoz A, Ducray F, Tholance Y, Barcelos
GK, Thomas-Maisonneuve L, Ghesquières H, Meyronet D, Quadrio I,
Cartalat-Carel S, Louis-Tisserand G, et al: CSF neopterin level as
a diagnostic marker in primary central nervous system lymphoma.
Neuro Oncol. 17:1497–1503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Caudie C, Bancel J, Dupont M, Matanza D,
Poitevin F and Honnorat J: CSF levels and diagnostic utility of
cerebrospinal fluid beta2-microglobulin. Ann Biol Clin (Paris).
63:631–637. 2005.
|
|
40
|
Strehlow F, Bauer S, Martus P, Weller M,
Roth P, Schlegel U, Seidel S, Scheibenbogen C, Korfel A and Kreher
S: Osteopontin in cerebrospinal fluid as diagnostic biomarker for
central nervous system lymphoma. J Neurooncol. 129:165–171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kersten MJ, Evers LM, Dellemijn PL, van
den Berg H, Portegies P, Hintzen RQ, van Lier RA, von dem Borne AE
and van Oers RH: Elevation of cerebrospinal fluid soluble CD27
levels in patients with meningeal localization of lymphoid
malignancies. Blood. 87:1985–1989. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baraniskin A, Kuhnhenn J, Schlegel U, Chan
A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A,
Schmiegel W, et al: Identification of microRNAs in the
cerebrospinal fluid as marker for primary diffuse large B-cell
lymphoma of the central system. Blood. 117:3140–3146. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zheng J, Xu J, Ma S, Sun X, Geng M and
Wang L: Clinicopathological study of gene rearrangement and
microRNA expression of primary central nervous system diffuse large
B-cell lymphomas. Int J Clin Exp Pathol. 6:2048–2055.
2013.PubMed/NCBI
|
|
44
|
Yu X, Li Z, Shen J, Chan MT and Wu WK:
Role of microRNAs in primary central nervous system lymphomas. Cell
Prolif. 49:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rimelen V, Ahle G, Pencreach E, Zinniger
N, Debliquis A, Zalmaï L, Harzallah I, Hurstel R, Alamome I, Lamy
F, et al: Tumor cell-free DNA detection in CSF for primary CNS
lymphoma diagnosis. Acta Neuropathol Commun. 7:432019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thaler FS, Laurent SA, Huber M, Mulazzani
M, Dreyling M, Ködel U, Kümpfel T, Straube A, Meinl E and von
Baumgarten L: Soluble TACI and soluble BCMA as biomarkers in
primary central nervous system lymphoma. Neuro Oncol. 19:1618–1627.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ho KG and Grommes C: Molecular profiling
of primary central nervous system lymphomas-predictive and
prognostic value? Curr Opin Neurol. 32:886–894. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Deguchi S, Nakashima K, Muramatsu K,
Mitsuya K, Oishi T, Shirata K, Hayashi N, Sugino T, Endo M and
Nakasu Y: Pretreatment intratumoral susceptibility signals
correlate with response to high-dose methotrexate and
progression-free survival in primary central nervous system
lymphoma. J Clin Neurosci. 69:43–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Phillips EH, Fox CP and Cwynarski K:
Primary CNS lymphoma. Curr Hematol Malig Rep. 9:243–253. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bataille B, Delwail V, Menet E,
Vandermarcq P, Ingrand P, Wager M, Guy G and Lapierre F: Primary
intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg.
92:261–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lim T, Kim SJ, Kim K, Lee JI, Lim DH, Lee
DJ, Baek KK, Lee HY, Han B, Uhm JE, et al: Primary CNS lymphoma
other than DLBCL: A descriptive analysis of clinical features and
treatment outcomes. Ann Hematol. 90:1391–1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Van Der Meulen M, Dinmohamed AG, Visser O,
Doorduijn JK and Bromberg JEC: Improved survival in primary central
nervous system lymphoma up to age 70 only: A population-based study
on incidence, primary treatment and survival in the Netherlands,
1989-2015. Leukemia. 31:1822–1825. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fallah J, Qunaj L and Olszewski AJ:
Therapy and outcomes of primary central nervous system lymphoma in
the United States: Analysis of the national cancer database. Blood
Adv. 1:112–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Graham MS and DeAngelis LM: Improving
outcomes in primary CNS lymphoma. Best Pract Res Clin Haematol.
31:262–269. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Glass J, Won M, Schultz CJ, Brat D,
Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK,
Augspurger M, et al: Phase I and II study of induction chemotherapy
with methotrexate, rituximab, and temozolomide, followed by
whole-brain radiotherapy and postirradiation temozolomide for
primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol.
34:1620–1625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Royer-Perron L and Hoang-Xuan K:
Management of primary central nervous system lymphoma. Presse Med.
47:e213–e244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kasenda B, Ferreri AJ, Marturano E, Forst
D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K,
Pulczynski EJ, et al: First-line treatment and outcome of elderly
patients with primary central nervous system lymphoma (PCNSL)-a
systematic review and individual patient data meta-analysis. Ann
Oncol. 26:1305–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Houillier C, Ghesquières H, Chabrot C,
Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO,
Vargaftig J, Gaultier C, et al: Rituximab, methotrexate,
procarbazine, vincristine and intensifified cytarabine
consolidation for primary central nervous system lymphoma (PCNSL)
in the elderly: A LOC network study. J Neurooncol. 133:315–320.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fritsch K, Kasenda B, Schorb E, Hau P,
Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, et al:
High-dose methotrexate-based immune-chemotherapy for elderly
primary CNS lymphoma patients (PRIMAIN study). Leukemia.
31:846–852. 2017. View Article : Google Scholar
|
|
60
|
Hoang-Xuan K, Taillandier L, Chinot O,
Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N,
Delattre JY and Baron B; European Organization for Research and
Treatment of Cancer Brain Tumor Group: Chemotherapy alone as
initial treatment for primary CNS lymphoma in patients older than
60 years: A multicenter phase II study (26952) of the European
organization for research and treatment of cancer brain tumor
group. J Clin Oncol. 21:2726–2731. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Illerhaus G, Marks R, Müller F, Ihorst G,
Feuerhake F, Deckert M, Ostertag C and Finke J: High-dose
methotrexate combined with procarbazine and CCNU for primary CNS
lymphoma in the elderly: Results of a prospective pilot and phase
II study. Ann Oncol. 20:319–325. 2009. View Article : Google Scholar
|
|
62
|
Roth P, Martus P, Kiewe P, Möhle R, Klasen
H, Rauch M, Röth A, Kaun S, Thiel E, Korfel A and Weller M: Outcome
of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1
trial. Neurology. 79:890–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Olivier G, Clavert A, Lacotte-Thierry L,
Gardembas M, Escoffre-Barbe M, Brion A, Cumin I, Legouffe E,
Solal-Celigny P, Chabin M, et al: A phase 1 dose escalation study
of idarubicin combined with methotrexate, vindesine, and
prednisolone for untreated elderly patients with primary central
nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol.
89:1024–1029. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Omuro A, Chinot O, Taillandier L,
Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S,
Soubeyran P, et al: Methotrexate and temozolomide vs. methotrexate,
procarbazine, vincristine, and cytarabine for primary CNS lymphoma
in an elderly population: An intergroup ANOCEF-GOELAMS randomized
phase 2 trial. Lancet Haematol. 2:e251–e259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pulczynski EJ, Kuittinen O, Erlanso M,
Hagberg H, Fosså A, Eriksson M, Nordstrøm M, Østenstad B, Fluge Ø,
Leppä S, et al: Successful change of treatment strategy in elderly
patients with primary central nervous system lymphoma by
de-escalating induction and introducing temozolomide maintenance:
Results from a phase II study by the Nordic Lymphoma Group.
Haematologica. 100:534–540. 2015. View Article : Google Scholar :
|
|
66
|
Mendez JS, Ostrom QT, Gittleman H, Kruchko
C, DeAngelis LM, Barnholtz-Sloan JS and Grommes C: The elderly left
behind-changes in survival trends of primary central nervous system
lymphoma over the past 4 decades. Neuro Oncol. 20:687–694. 2018.
View Article : Google Scholar
|
|
67
|
Langner-Lemercier S, Houillier C, Soussain
C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T,
Morschhauser F, Benouaich-Amiel A, et al: Primary CNS lymphoma at
first relapse/progression: Characteristics, management, and outcome
of 256 patients from The French LOC network. Neuro Oncol.
18:1297–1303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jahnke K, Thiel E, Martus P, Herrlinger U,
Weller M, Fischer L and Korfel A; German Primary Central Nervous
System Lymphoma Study Group: Relapse of primary central nervous
system lymphoma: Clinical features, outcome and prognostic factors.
J Neurooncol. 80:159–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nayak L, Hedvat C, Rosenblum MK, Abrey LE
and DeAngelis LM: Late relapse in primary central nervous system
lymphoma: Clonal persistence. Neuro Oncol. 13:525–529. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Abrey LE, Ben-Porat L, Panageas KS,
Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta
M and DeAngelis LM: Primary central nervous system lymphoma: The
memorial Sloankettering cancer Center prognostic model. J Clin
Oncol. 24:5711–5715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ferreri AJ, Blay JY, Reni M, Pasini F,
Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi
A, et al: Prognostic scoring system for primary CNS lymphomas: The
International extranodal lymphoma study group experience. J Clin
Oncol. 21:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Weller M, Martus P, Roth P, Thiel E and
Korfel A; German PCNSL Study Group: Surgery for primary CNS
lymphoma? Challenging a paradigm. Neuro Oncol. 14:1481–1484. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Makino K, Nakamura H, Hide T, Kuroda J,
Yano S and Kuratsu J: Prognostic impact of completion of initial
high-dose methotrexate therapy on primary central nervous system
lymphoma: A single institution experience. Int J Clin Oncol.
20:29–34. 2015. View Article : Google Scholar
|
|
74
|
Nakasu Y, Mitsuya K, Hayashi N, Okamura I,
Mori K, Enami T, Tatara R, Nakasu S and Ikeda T: Response-adapted
treatment with upfront high-dose chemotherapy followed by
autologous stem-cell transplantation rescue or consolidation phase
high-dose methotrexate for primary central nervous system lymphoma:
A long-term mono-center study. Springerplus. 5:3072016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kondo E, Ikeda T, Izutsu K, Chihara D,
Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, et
al: High dose chemotherapy with autologous stem cell
transplantation in primary central nervous system lymphoma: Data
from the Japan Society for Hematopoietic Cell Transplantation
(JSHCT) registry. Biol Blood Marrow Transplant. 25:899–905. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Levy O, DeAngelis LM, Filippa DA, Panageas
KS and Abrey LE: Bcl-6 predicts improved prognosis in primary
central nervous system lymphoma. Cancer. 112:151–156. 2008.
View Article : Google Scholar
|
|
77
|
Preusser M, Woehrer A, Koperek O,
Rottenfusser A, Dieckmann K, Gatterbauer B, Roessler K, Slavc I,
Jaeger U, Streubel B, et al: Primary central nervous system
lymphoma: A clinicopathological study of 75 cases. Pathology.
42:547–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Niparuck P, Boonsakan P, Sutthippingkiat
T, Pukiat S, Chantrathammachart P, Phusanti S, Boonyawat K,
Puavilai T, Angchaisuksiri P, Ungkanont A, et al: Treatment outcome
and prognostic factors in PCNSL. Diagn Pathol. 14:562019.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chen C, Zhuo H, Wei X and Ma X:
Contrast-enhanced MRI texture parameters as potential prognostic
factors for primary central nervous system lymphoma patients
receiving high-dose methotrexate-based chemotherapy. Contrast Media
Mol Imaging. 2019:54814912019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Alame M, Pirel M, Costes-Martineau V,
Bauchet L, Fabbro M, Tourneret A, De Oliveira L, Durand L, Roger P,
Gonzalez S, et al: Characterisation of tumour microenvironment and
immune checkpoints in primary central nervous system diffuse large
B cell lymphomas. Virchows Arch. 476:891–902. 2020. View Article : Google Scholar
|
|
81
|
Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim
WS and Kim SJ: Serum levels of soluble programmed death-ligand 1
(sPD-L1) in patients with primary central nervous system diffuse
large B-cell lymphoma. BMC Cancer. 20:1202020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cambruzzi E: Primary intra-axial diffuse
large b-cell lymphoma in immunocompetent patients: Clinical impact
of molecular analysis and histogenetic evaluation. World Neurosurg.
134:215–220. 2020. View Article : Google Scholar
|
|
83
|
Yuan XG, Huang YR, Yu T, Xu Y, Liang Y,
Zhang XH, Sun CR and Zhao XY: Primary central nervous system
lymphoma in China: A single-center retrospective analysis of 167
cases. Ann Hematol. 99:93–104. 2020. View Article : Google Scholar
|
|
84
|
Tabouret E, Houillier C, Martin-Duverneuil
N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D,
Soubeyran P, Gressin R, et al: Patterns of response and relapse in
primary CNS lymphomas after first-line chemotherapy: Imaging
analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro
Oncol. 19:422–429. 2017.
|
|
85
|
Chunsong H, Yuling H, Li W, Jie X, Gang Z,
Qiuping Z, Qingping G, Kejian Z, Li Q, Chang AE, et al: CXC
chemokine ligand 13 and CC chemokine ligand 19 cooperatively render
resistance to apoptosis in B cell lineage acute and chronic
lymphocytic leukemia CD23+CD5+ B cells. J Immunol. 177:6713–6722.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Le M, Garcilazo Y, Ibáñez-Juliá MJ, Younan
N, Royer-Perron L, Benazra M, Mokhtari K, Houillier C, Hoang-Xuan K
and Alentorn A: Pretreatment hemoglobin as an independent
prognostic factor in primary central nervous system lymphomas.
Hematologic malignancies. Oncologist. 24:e898–e904. 2019.
View Article : Google Scholar
|
|
87
|
Oyama T, Yamamoto K, Asano N, Oshiro A,
Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, et
al: Age-related EBV associated B-cell lymphoproliferative disorders
constitute a distinct clinicopathologic group: A study of 96
patients. Clin Cancer Res. 13:5124–5132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wu T, Kang H, Zhuang D, Ma Y, Lin Z,
Suolitiken D, Chen B and Xu X: The role of ABCB1 polymorphism as a
prognostic marker for primary central nervous system lymphoma. Ann
Hematol. 98:923–930. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang X, Wang Y, Sun X, Bai X, Cui Q, Zhu
H, Qian J, Chen Y, Sun S, Ji N, et al: STAT3 activation is
associated with IL-10 expression and survival in primary central
nervous system lymphoma. World Neurosurg. 134:e1077–e1084. 2020.
View Article : Google Scholar
|
|
90
|
Hatzl S, Posch F, Deutsch A, Beham-Schmid
C, Stöger H, Greinix H, Pichler M, Neumeister P and Prochazka KT:
Immunohistochemistry for c-myc and bcl-2 overexpression improves
risk stratification in primary central nervous system lymphoma
(PCNSL). Hematol Oncol. 38:277–283. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yin W, Xia X, Wu M, Yang H, Zhu X, Sun W
and Ge M: The impact of BCL-2/MYC protein expression and gene
abnor-mality on primary central nervous system diffuse large B-cell
lymphoma. Int J Clin Exp Pathol. 12:2215–2223. 2019.
|
|
92
|
Villa D, Tan KL, Steidl C, Ben-Neriah S,
Al Moosawi M, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Scott
DW, et al: Molecular features of a large cohort of primary central
nervous system lymphoma using tissue microarray. Blood Adv.
3:3953–3961. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Takano S, Hattori K, Ishikawa E, Narita Y,
Iwadate Y, Yamaguchi F, Nagane M, Akimoto J, Oka H, Tanaka S, et
al: MyD88 mutation in elderly predicts poor prognosis in primary
central nervous system lymphoma: Multi-institutional analysis.
World Neurosurg. 112:e69–e73. 2018. View Article : Google Scholar
|
|
94
|
Nayyar N, White MD, Gill CM, Lastrapes M,
Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, et
al: MYD88 L265P mutation and CDKN2A loss are early mutational
events in primary central nervous system diffuse large B-cell
lymphomas. Blood Adv. 3:375–383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Mondello P, Cuzzocrea S, Arrigo C, Pitini
V, Mian M and Bertoni F: STAT6 activation correlates with
cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary
Central Nervous System Lymphoma. Hematol Oncol. 38:106–110. 2020.
View Article : Google Scholar
|
|
96
|
Hyung J, Hong JY, Kim S, Ryu JS, Huh J and
Suh C: Beta-2 microglobulin as a prognostic factor of primary
central nervous system lymphoma. Blood Res. 54:285–288. 2019.
View Article : Google Scholar
|
|
97
|
Kim S, Nam SJ, Park C, Kwon D, Yim J, Song
SG, Ock CY, Kim YA, Park SH, Kim TM, et al: High tumoral PD-L1
expression and low PD-1 + or CD8 + tumor-infiltrating lymphocytes
are predictive of a poor prognosis in primary diffuse large B-cell
lymphoma of the central nervous system. Oncoimmunology.
8:e16266532019. View Article : Google Scholar
|
|
98
|
Gopal S, Martin KE, Richards KL and Eron
JJ: Clinical presentation, treatment, and outcomes among 65
patients with HIV-associated lymphoma treated at the University of
North Carolina 2000-2010. AIDS Res Hum Retroviruses. 28:798–805.
2012. View Article : Google Scholar :
|
|
99
|
Han CH and Batchelor TT: Diagnosis and
management of primary central nervous system lymphoma. Cancer.
123:4314–4324. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Corry J, Smith JG, Wirth A, Quong G and
Liew KH: Primary central nervous system lymphoma: Age and
performance status are more important than treatment modality. Int
J Radiat Oncol Biol Phys. 41:615–620. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Mohile SG, Dale W, Somerfield MR,
Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM,
Hopkins JO, et al: Practical Assessment and Management of
Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO
Guideline for Geriatric Oncology. J Clin Oncol. 36:2326–2347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Extermann M, Boler I, Reich RR, Lyman GH,
Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ
III and Balducci L: Predicting the risk of chemotherapy toxicity in
older patients: The chemotherapy risk assessment scale for high-age
patients (CRASH) score. Cancer. 118:3377–3386. 2012. View Article : Google Scholar
|
|
103
|
Hiraga S, Arita N, Ohnishi T, Kohmura E,
Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K and Yoshimine T: Rapid
infusion of high-dose methotrexate resulting in enhanced
penetration into cerebrospinal fluid and intensified tumor response
in primary central nervous system lymphomas. J Neurosurg.
91:221–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Glass J, Shustik C, Hochberg FH, Cher L
and Gruber ML: Therapy of primary central nervous system lymphoma
with pre-irradiation methotrexate, cyclophosphamide, doxorubicin,
vincristine, and dexamethasone (MCHOD). J Neurooncol. 30:257–265.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Binnahil M, Au K, Lu JQ, Wheatley BM and
Sankar T: The influence of Cortico-steroids on diagnostic accuracy
of biopsy for primary central nervous system lymphoma. Can J Neurol
Sci. 43:721–725. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Porter AB, Giannini C, Kaufmann T,
Lucchinetti CF, Wu W, Decker PA, Atkinson JL and O'Neill BP:
Primary central nervous system lymphoma can be histologically
diagnosed after previous corticosteroid use: A pilot study to
determine whether corticosteroids prevent the diagnosis of primary
central nervous system lymphoma. Ann Neurol. 63:662–667. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mathew BS, Carson KA and Grossman SA:
Initial response to glucocorticoids: A potentially important
prognostic factor in patients with primary CNS lymphoma. Cancer.
106:383–387. 2006. View Article : Google Scholar
|
|
108
|
Batchelor TT: Primary central nervous
system lymphoma: A curable disease. Hematol Oncol. 37(Suppl 1):
S15–S18. 2019. View Article : Google Scholar
|
|
109
|
Nabors LB, Portnow J, Baehring J, Brem H,
Butowski N, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C,
Howard S, et al: NCCN Clinical Practice Guidelines in Oncology.
Central Nervous System Cancers. 1:32–35. 2018.
|
|
110
|
Rushworth D, Mathews A, Alpert A and
Cooper LJ: Dihydrofolate reductase and thymidylate synthase
transgenes resistant to methotrexate interact to permit novel
transgene regulation. J Biol Chem. 290:22970–22976. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Goecke IA, Alvarez C, Henríquez J, Salas
K, Molina ML, Ferreira A and Gatica H: Methotrexate regulates the
expres-sion of glucocorticoid receptor alpha and beta isoforms in
normal human peripheral mononuclear cells and human lymphocyte cell
lines in vitro. Mol Immunol. 44:2115–2123. 2007. View Article : Google Scholar
|
|
112
|
Madle M, Krämer I, Lehners N, Schwarzbich
M, Wuchter P, Herfarth K, Egerer G, Ho AD and Witzens-Harig M: The
influence of rituximab, high-dose therapy followed by autologous
stem cell transplantation, and age in patients with primary CNS
lymphoma. Ann Hematol. 94:1853–1857. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Rubenstein JL, Hsi ED, Johnson JL, Jung
SH, Nakashima MO, Grant B, Cheson BD and Kaplan LD: Intensive
chemotherapy and immunotherapy in patients with newly diagnosed
primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol.
31:3061–3068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Jahnke K, Korfel A, Martus P, Weller M,
Herrlinger U, Schmittel A, Fischer L and Thiel E; German Primary
Central Nervous System Lymphoma Study Group (G-PCNSL-SG): High-dose
methotrexate toxicity in elderly patients with primary central
nervous system lymphoma. Ann Oncol. 16:445–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Welch MR, Omuro A and Deangelis LM:
Outcomes of the oldest patients with primary CNS lymphoma treated
at Memorial Sloan-Kettering Cancer Center. Neuro Oncol.
14:1304–1311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Illerhaus G, Schorb E and Kasenda B: Novel
agents for primary central nervous system lymphoma: Evidence and
perspectives. Blood. 132:681–688. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Faivre G, Butler MJ, Le I and Brenner A:
Temozolomide as a single agent maintenance therapy in elderly
patients with primary CNS lymphoma. Clin Lymphoma Myeloma Leuk.
19:665–669. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Shih C, Chen VJ, Gossett LS, Gates SB,
MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ,
Patel VF, et al: LY231514, a pyrrolo[2,3-d] pyrimidine-based
antifolate that inhibits multiple folate-requiring enzymes. Cancer
Res. 57:1116–1123. 1997.PubMed/NCBI
|
|
119
|
Raizer JJ, Rademaker A, Evens AM, Rice L,
Schwartz M, Chandler JP, Getch CC, Tellez C and Grimm SA:
Pemetrexed in the treatment of relapsed/refractory primary central
nervous system lymphoma. Cancer. 118:3743–3748. 2012. View Article : Google Scholar
|
|
120
|
Han S, Wang M, Liu B and Yu J: Pemetrexed
for primary central nervous system lymphoma in the elderly. Clin
Transl Oncol. 18:138–143. 2016. View Article : Google Scholar
|
|
121
|
Pardridge WM: BBB-genomics: Creating new
openings for brain-drug targeting. Drug Discovery Today. 6:381–383.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Thiel E, Korfel A, Martus P, Kanz L,
Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T,
Hundsberger T, et al: High-dose methotrexate with or without whole
brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase
3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–1047.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Birnbaum T, Stadler EA, von Baumgarten L
and Straube A: Rituximab significantly improves complete response
rate in patients with primary CNS lymphoma. J Neurooncol.
109:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Holdhoff M, Ambady P, Abdelaziz A, Sarai
G, Bonekamp D, Blakeley J, Grossman SA and Ye X: High-dose
methotrexate with or without rituximab in newly diagnosed primary
CNS lymphoma. Neurology. 83:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Miyakita Y, Ohno M, Takahashi M, Muragaki
Y, Katai H and Narita Y: Immunochemotherapy using rituximab (RTX)
and high-dose methotrexate (HD-MTX): An evaluation of the addition
of RTX to HD-MTX in recurrent primary central nervous system
lymphoma (PCNSL). Jpn J Clin Oncol. 47:919–924. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Fritsch K, Kasenda B, Hader C, Nikkhah G,
Prinz M, Haug V, Haug S, Ihorst G, Finke J and Illerhaus G:
Immunochemotherapy with rituximab, methotrexate, procarbazine, and
lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann
Oncol. 22:2080–2085. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Iwamoto FM, Schwartz J, Pandit-Taskar N,
Peak S, Divgi CR, Zelenetz AD, Humm J and Abrey LE: Study of
radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in
primary central nervous system lymphoma. Cancer. 110:2528–2534.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ferreri AJ, Cwynarski K, Pulczynski E,
Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb
E, et al: Chemoimmunotherapy with methotrexate, cytarabine,
thiotepa, and rituximab (MATRix regimen) in patients with primary
CNS lymphoma: Results of the first randomisation of the
International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2
trial. Lancet Haematol. 3:e217–e227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Schmitt AM, Herbrand AK, Fox CP, Bakunina
K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus
G, Issa S, et al: Rituximab in primary central nervous system
lymphoma-a systematic review and Meta-analysis. Hematol Oncol.
37:548–557. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Bromberg JEC, Issa S, Bakunina K, Minnema
MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra
JM, et al: Rituximab in patients with primary CNS lymphoma (HOVON
105/ALLG NHL 24): A randomised, open-label, phase 3 inter-group
Study. Lancet Oncol. 20:216–228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Han X, Ji Y, Ouyang M, Zhu T and Zhou D:
Efficacy and safety of HD-MTX based systemic chemotherapy regimens:
Retrospective study of induction therapy for primary central
nervous system lymphoma in Chinese. Sci Rep. 7:170532017.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Poortmans PM, Kluin-Nelemans HC,
Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, Taphoorn M,
Thomas J, Van den Bent M, Fickers M, et al: High-dose
methotrexate-based chemotherapy followed by consolidating
radiotherapy in non-AIDS-related primary central nervous system
lymphoma: European organization for research and treatment of
cancer lymphoma group phase II trial 20962. J Clin Oncol.
21:4483–4488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
van Tellingen O, Boogerd W, Nooijen WJ and
Beijnen JH: The vascular compartment hampers accurate determination
of teniposide penetration into braintumor tissue. Cancer Chemother
Pharmacol. 40:330–334. 1997. View Article : Google Scholar
|
|
134
|
Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X,
Li L, Wang X, Zhang X, Li Z, et al: Fotemustine, teniposide and
dexametha-sone versus high-dose methotrexate plus cytarabine in
newly diagnosed primary CNS lymphoma: A randomised phase 2 trial. J
Neurooncol. 140:427–434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wang YX, Huang Y, Xu XP, Chen BB, Lin ZG,
Ma Y, Ding TL and Wang Q: Curative effect of methotrexate combined
with teniposide in the treatment of primary central nervous system
lymphoma. Oncol Lett. 19:2097–2106. 2020.PubMed/NCBI
|
|
136
|
Deng X, Xu X, Lin D, Zhang X, Yu L, Sheng
H, Yin B, Zhang N and Lin J: Real-world impact of surgical excision
on overall survival in primary central nervous system lymphoma.
Front Oncol. 10:1312020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Kinslow CJ, Rae AI, Neugut AI, Adams CM,
Cheng SK, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Iwamoto FM, et
al: Surgery plus adjuvant radiotherapy for primary central nervous
system lymphoma. Br J Neurosurg. 34:690–696. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Korfel A and Schlegel U: Diagnosis and
treatment of primary CNS lymphoma. Nat Rev Neurol. 9:317–327. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Schlegel U and Korfel A: Is whole-brain
radiotherapy still a standard treatment for primary central nervous
system lymphomas? Curr Opin Neurol. 31:733–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Shah GD, Yahalom J, Correa DD, Lai RK,
Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM and Abrey LE:
Combined immunochemotherapy with reduced whole-brain radiotherapy
for newly diagnosed primary CNS lymphoma. J Clin Oncol.
25:4730–4735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lee TH, Lee JH, Chang JH, Ye SJ, Kim TM,
Park CK, Kim IH, Kim BH and Wee CW: Reduced-dose whole-brain
radiotherapy with tumor bed boost after upfront high-dose
methotrexate for primary central nervous system lymphoma. Radiat
Oncol J. 38:35–43. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Gaut D and Schiller GJ: Hematopoietic stem
cell transplantation in primary central nervous system lymphoma: A
review of the literature. Int J Hematol. 109:260–277. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Schorb E, Fox CP, Fritsch K, Isbell L,
Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O,
De-Silva D, et al: High-dose thiotepa-based chemotherapy with
autologous stem cell support in elderly patients with primary
central nervous system lymphoma: A European retrospective study.
Bone Marrow Transplant. 52:1113–1119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Vu K, Mannis G, Hwang J, Geng H and
Rubenstein JL: Low-dose lenalidomide maintenance after induction
therapy in older patients with primary central nervous system
lymphoma. Br J Haematol. 186:180–183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Bairey O and Siegal T: The possible role
of maintenance treatment for primary central nervous system
lymphoma. Blood Rev. 32:378–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Reni M and Ferreri AJ: Therapeutic
management of refractory or relapsed primary central nervous system
lymphomas. Ann Hematol. 80(Suppl 3): B113–B117. 2001.
|
|
147
|
Otani R, Yamada R, Kushihara Y, Inazuka M
and Shinoura N: Continuous intrathecal injection therapy of
methotrexate is a therapeutic option in primary CNS lymphoma. J
Clin Neurosci. 69:26–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Soussain C, Suzan F, Hoang-Xuan K, Cassoux
N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, et al:
Results of intensive chemotherapy followed by hematopoietic
stem-cell rescue in 22 patients with refractory or recurrent
primary CNS lymphoma or intraocular lymphoma. J Clin Oncol.
19:742–749. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Correa DD, Braun E, Kryza-Lacombe M, Ho
KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE,
DeAngelis LM, et al: Longitudinal cognitive assessment in patients
with primary CNS lymphoma treated with induction chemotherapy
followed by reduced-dose whole-brain radiotherapy or autologous
stem cell transplantation. J Neurooncol. 144:553–562. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Atilla E, Sahin U, Atilla PA, Merter M,
Ozyurek E, Ceyhan K and Bozdag SC: Allogeneic stem cell
transplantation for relapsed primary central nervous system
lymphoma: Is it feasible? Hematol Oncol Stem Cell Ther. 12:220–225.
2019. View Article : Google Scholar
|
|
151
|
Varadi G, Or R, Kapelushnik J, Naparstek
E, Nagler A, Brautbar C, Amar A, Kirschbaum M, Samuel S, Slavin S
and Siegal T: Graft-versus-lymphoma effect after allogeneic
peripheral blood stem cell transplantation for primary central
nervous system lymphoma. Leuk Lymphoma. 34:185–190. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Tu S, Zhou X, Guo Z, Huang R, Yue C, He Y,
Li M, Chen Y, Liu Y, Chang LJ and Li Y: CD19 and CD70 Dual-target
chimeric antigen receptor T-cell therapy for the treatment of
relapsed and refractory primary central nervous system diffuse
large B-cell lymphoma. Front Oncol. 9:13502019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Lionakis MS, Dunleavy K, Roschewski M,
Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C,
Higham CS, et al: Inhibition of B cell receptor signaling by
Ibrutinib in primary CNS lymphoma. Cancer Cell. 31:833–843.e5.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Narita Y, Nagane M, Mishima K, Terui Y,
Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N,
et al: Phase 1/2 study of tirabrutinib, a second-generation
Bruton's tyro-sine kinase inhibitor, in relapsed/refractory primary
central nervous system lymphoma. Neuro Oncol. noaa1452020.
View Article : Google Scholar : Epub ahead of
print.
|
|
155
|
Tun HW, Johnston PB, DeAngelis LM,
Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff
D, O'Neill B, et al: Phase I study of pomalidomide and
dexamethasone for relapsed/refractory primary CNS or vitreoretinal
lymphoma. Blood. 132:2240–2248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Nayak L, Iwamoto FM, LaCasce A, Mukundan
S, Roemer MGM, Chapuy B, Armand P, Rodig SJ and Shipp MA: PD-1
blockade with nivolumab in relapsed/refractory primary central
nervous system and testicular lymphoma. Blood. 129:3071–3073. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Ferry JA: The diversity of diffuse large
B-cell lymphoma in extranodal sites: Overview and update. J
Hematopathol. 7:57–70. 2014. View Article : Google Scholar
|
|
158
|
Chamoun K, Choquet S, Boyle E, Houillier
C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V,
Morschhauser F, Hoang-Xuan K and Soussain C: Ibrutinib monotherapy
in relapsed/refractory CNS lymphoma: A retrospective case series.
Neurology. 88:101–102. 2017. View Article : Google Scholar
|
|
159
|
Grommes C, Pastore A, Palaskas N, Tang SS,
Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, et al:
IbrutInib unmasks critical role of Bruton tyrosine kinase in
primary CNS lymphoma. Cancer Discov. 7:1018–1029. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Soussain C, Choquet S, Blonski M, Leclercq
D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, et
al: Ibrutinib monotherapy for relapse or refractory primary CNS
lymphoma and primary vitreoretinal lymphoma: Final analysis of the
phase II 'proof-of-concept' iLOC study by the Lymphoma study
association (LYSA) and the French oculo-cerebral lymphoma (LOC)
network. Eur J Cancer. 117:121–130. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Yang Y, Shaffer AL III, Emre NC, Ceribelli
M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, et
al: Exploiting synthetic lethality for the therapy of ABC diffuse
large B cell lymphoma. Cancer Cell. 21:723–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Houillier C, Choquet S, Touitou V,
Martin-Duverneuil N, Navarro S, Mokhtari K, Soussain C and
Hoang-Xuan K: Lenalidomide monotherapy as salvage treatment for
recurrent primary CNS lymphoma. Neurology. 84:325–326. 2015.
View Article : Google Scholar
|
|
163
|
Rubenstein JL, Geng H, Fraser EJ, Formaker
P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, et
al: Phase 1 investigation of lenalidomide/rituximab plus outcomes
of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv.
2:1595–1607. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Ghesquieres H, Chevrier M, Laadhari M,
Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R,
Morschhauser F, Schmitt A, et al: Lenalidomide in combination with
intrave-nous rituximab (REVRI) in relapsed/refractory primary CNS
lymphoma or primary intraocular lymphoma: A multicenter prospective
'proof of concept' phase II study of the French Oculo-Cerebral
lymphoma (LOC) Network and the Lymphoma Study Association (LYSA).
Ann Oncol. 30:621–628. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Takashima Y, Sasaki Y, Hayano A, Homma J,
Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Tokino T and
Yamanaka R: Target amplicon exomesequencing identifies promising
diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT
signaling as central oncopathways in primary central nervous system
lymphoma. Oncotarget. 9:27471–27486. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Todorovic Balint M, Jelicic J, Mihaljevic
B, Kostic J, Stanic B, Balint B, Pejanovic N, Lucic B, Tosic N,
Marjanovic I, et al: Gene mutation profiles in primary diffuse
large B cell lymphoma of central nervous system: Next generation
sequencing analyses. Int J Mol Sci. 17:6832016. View Article : Google Scholar :
|
|
167
|
Zhang X and Liu Y: Targeting the the
PI3K/AKT/mTOR signaling pathway in primary central nervous system
lymphoma: Current status and future prospects. CNS Neurol Disord
Drug Targets. 19:165–173. 2020. View Article : Google Scholar
|
|
168
|
Korfel A, Schlegel U, Herrlinger U,
Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T,
Kebir S, Thiel E, et al: Phase II trial of temsirolimus for
Relapsed/Refractory primary CNS lymphoma. J Clin Oncol.
34:1757–1763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Grommes C, Pentsova E, Nolan C, Wolfe J,
Mellinghoff IK and Deangelis L: Phase II study of single agent
buparlisib in recurrent/refractory primary (PCNSL) and secondary
CNS lymphoma (SCNSL). Ann Oncol. 27(Suppl 6): vi103–vi113.
2016.
|
|
170
|
Ezell SA, Mayo M, Bihani T, Tepsuporn S,
Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer
C, et al: Synergistic induction of apoptosis by combination of BTK
and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Oncotarget. 5:4990–5001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Tarantelli C, Gaudio E, Arribas AJ, Kwee
I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E,
Guidetti F, et al: PQR309 is a novel dual PI3K/mTOR inhibitor with
preclinical antitumor activity in lymphomas as a single agent and
in combination therapy. Clin Cancer Res. 24:120–129. 2018.
View Article : Google Scholar
|
|
172
|
Furuse M, Nonoguchi N, Omura N, Shirahata
M, Iwasaki K, Inui T, Kuroiwa T, Kuwabara H and Miyatake SI:
Immunotherapy of Nivolumab with dendritic cell vaccination is
effective against intractable recurrent primary central nervous
system lymphoma: A case report. Neurol Med Chir (Tokyo).
57:191–197. 2017. View Article : Google Scholar
|
|
173
|
Chan TSY, Khong PL, Au-Yeung R, Kwong YL
and Tse E: Low-dose nivolumab induced durable complete response in
relapsed primary central nervous system diffuse large B cell
lymphoma. Ann Hematol. 98:2227–2230. 2019. View Article : Google Scholar : PubMed/NCBI
|
